Oncology and Carcinogenesis articles for Harvard University, United States of America (USA)

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 426

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
2 0.73
Arginine Polymer-Based Nanoplatform Facilitates Oral Co-Delivery of Antibody/Antigen for Robust Oral Immunotherapy in Orthotopic Colon Cancer 0.08
A Myeloid Cell-Targeted Immunostimulant Cocktail (MyTai) Enhances Cancer Immunotherapy 0.65
4 1.82
MSH3 is a genetic modifier of somatic repeat instability in X-linked dystonia parkinsonism 0.69
Discovery of small molecules and a druggable groove that regulate DNA binding and release of the AP-1 transcription factor ΔFOSB 0.10
Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity 0.21
Changes in patient-reported quality of life after lobectomy versus sublobar resection 0.81
2 0.29
A Tumor-Targeted tRF Therapeutics Triggers Ovarian Cancer Ferroptosis via Dual Inhibition of System Xc− 0.20
Photoinduced Plasmon Electron Transfer‐based Bioorthogonal Cleavage Reaction for Precision Tumor Therapy 0.09
2 1.30
Pre-diagnostic Body Mass Index Trajectories and Associations with Lung Cancer Risk 0.40
Guideline-based physical activity and health-related quality of life among prostate cancer survivors: a target trial emulation in the Health Professionals Follow-up Study 0.90
2 0.10
Bi-allelic variants in neuronal adhesion molecule astrotactin 1 gene ASTN1 cause diverse neurodevelopmental disorders 0.07
Large-scale integration of omics and electronic health records to identify potential risk protein biomarkers and therapeutic drugs for cancer prevention 0.03
1 0.05
A trans-omics gene-smoking interaction study of lung cancer based on consortium data 0.05
1 0.11
Neo‐Cysteine Molecular Glues for Targeting Mutated SMAD4 Protein 0.11
5 0.44
The International Study Group for Pancreatic Surgery (ISGPS) Definition and Classification of Postpancreatectomy Mortality. 0.05
Accuracy of Histology and Malignancy Grade between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study from the Prospective Retroperitoneal Sarcoma Registry (Resar). 0.06
Implementation of Comprehensive Surgical Guidelines for Hepatoblastoma: Analysis of the Children's Oncology Group AHEP0731 Phase III Trial. 0.09
International Validation of a Recurrence Risk Model for Stage II Colon Cancer: The SPHERE Study. 0.14
Clinical and Pathologic features of 535 Patients with Congenital Mesoblastic Nephroma: A Report from the Children's Oncology Group. 0.09
18 5.42
Inflammatory bowel disease–induced inflammation augments clonal hematopoiesis of indeterminate potential through Ref-1 0.28
Ruxolitinib for ciltacabtagene autoleucel–associated refractory diarrhea 0.88
Immune biomarkers of increased infection risk in multiple myeloma 0.05
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma 0.04
Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH) 0.04
Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08 0.23
Impact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials 0.36
Menin inhibition with revumenib for iNPM1/i-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study 0.03
A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma 0.04
ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia 0.07
A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma 0.90
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia 0.02
Itacitinib for the prevention of IEC therapy–associated CRS: results from the 2-part phase 2 INCB 39110-211 study 0.07
Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of iJAK2/i-mutated post-MPN AML 0.03
The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NFκB signaling 0.08
Clinical presentation, management and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy 0.90
Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma 0.73
Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q+ 0.66
15 2.80
Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer 0.89
Whole-genome doubling drives immune evasion by silencing antigen presentation 0.69
Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression 0.54
Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity 0.02
A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies 0.11
Male-biased Yap1-Cd276/B7-H3 axis for immune evasion in medulloblastoma 0.06
Characterization of a pathogenic subpopulation of human glioma associated macrophages linked to glioma progression 0.18
Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence 0.02
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma 0.01
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF metastatic colorectal cancer 0.03
CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases 0.00
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer 0.03
Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures 0.21
Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy 0.00
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma 0.00
16 4.55
Loss of JAK1 Function Causes G2–M Cell-Cycle Defects Vulnerable to KIF18A Inhibition 0.02
KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment 0.08
Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer 0.04
A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules 0.04
Integrative Multiomic Classification Reveals Distinct Origins and Evolutionary Trajectories of Thymic Epithelial Tumors 0.02
EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators 0.82
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. 0.08
Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma. 0.13
Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment 0.71
EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression. 0.20
Fibroblast STAT3 Activation Drives Organ-Specific Premetastatic Niche Formation. 0.05
Radiation-Triggered Payload Release Enhances Bispecific Antibody Efficacy. 1.00
CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer 0.41
Epigenetic De-repression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression. 0.62
Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer 0.14
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect 0.20
11 5.01
Nociceptive innervation limits tertiary lymphoid structures to promote lung cancer 0.10
Cell-autonomous control of CAR signaling and receptor shedding via ADAM17-mediated proteolysis 0.00
Biodiversity and biogeography of the multi-kingdom cancer microbiome 0.43
Disrupted molecular glue complex drives RAS inhibitor resistance 0.04
ErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imaging 0.55
Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial 0.81
Inhibition of oligomeric BAX by an anti-apoptotic dimer 0.67
Design of soluble Notch agonists that drive T cell development and boost immunity 0.82
Regulation of inflammatory responses by pH-dependent transcriptional condensates 0.64
A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma 0.95
Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis 0.00
1 0.80
Long-lasting gut microbiome and fecal metabolome alterations after colorectal adenoma removal and their relationship to colorectal cancer 0.80
2 0.92
Mitochondrial transfer from immune to tumor cells enables lymph node metastasis 0.05
OGFOD1 enables AML chemo- and nutrient stress resistance by regulating protein synthesis 0.87
1 0.54
HBO1 functions as an epigenetic barrier to hepatocyte plasticity and reprogramming during liver injury 0.54
2 1.65
The 2021 US Preventive Services Task Force Lung Cancer Screening Criteria Miss Many Patients Diagnosed With Early and Late-Stage Lung Cancer 0.75
Segmentectomy versus Lobectomy for Patients with 2-3cm Non-Small-Cell Lung Cancer 0.90
3 1.89
Multiscale mechanisms driving tissue rupture by invading cells 0.01
Loss of NOTCH2 creates a TRIM28-dependent vulnerability in small cell lung cancer 0.88
AKT-mediated phosphorylation of TSC2 controls stimulus- and tissue-specific mTORC1 signaling and organ growth 1.00
1 0.75
Cigarette smoking and long-term incidence of colorectal cancer subclassified by tumor-infiltrating myeloid cells: A prospective cohort study 0.75
3 0.24
Histopathology-based Artificial Intelligence Algorithms for the Prediction of Prostate Cancer Metastasis After Radical Prostatectomy 0.09
Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer 0.06
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial 0.10
3 0.85
Interventions for Increasing Colorectal Cancer Screening Uptake: A Systematic Review and Network Meta-Analysis 0.04
Fecal Detection of Calprotectin Subunits Links Inflammatory Bowel Disease Activity With Chronicity of Intestinal Inflammation 0.01
Chemical perturbations impacting histone acetylation govern colorectal cancer differentiation 0.80
1 0.94
Multiomic analysis of clonal development reveals new regulators of leukemic cell growth 0.94
1 0.66
Comparative risk of high-risk neoplasia after polypectomy among individuals aged below 50 years versus 50 years and older 0.66
1 0.01
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses. 0.01
5 0.36
Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment 0.00
Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity 0.00
IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy 0.04
IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy 0.00
Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer 0.31
2 0.13
The impact of an organized screening program on gastric cancer incidence: a quasi-experimental study 0.07
Investigating the association between anthropometry and colorectal cancer survival: a two-sample Mendelian randomization analysis 0.06
1 0.61
Mailed Outreach for Colorectal Cancer Screening in Community Health Centers 0.61
1 0.57
Long-Term Locoregional Outcomes in a Contemporary Cohort of Young Women With Breast Cancer 0.57
2 0.08
Biomarker-Based Eligibility for Lung Cancer Screening: Validation of the Protein-Based INTEGRAL-Risk Model. 0.03
Clinical Validation of a Circulating Tumor DNA–Based Blood Test to Screen for Colorectal Cancer 0.05
5 2.52
Dysregulated HELLS expression alters cellular processes and serves as a potential prognostic marker in acute myeloid leukemia 0.06
Structural Basis for Substrate Recruitment and Catalytic Ubiquitin Transfer by the E2/E3 Hybrid Enzyme UBE2O. 0.04
A Modular Uba1-Nanobody Fusion Enables Selective Ubiquitin Transfer to Tagged E2 Enzymes 0.42
Characterization and inhibitor sensitivity of ARAF, BRAF, and CRAF kinases 1.00
Nanobodies targeting EGFR provide insight into conformations stabilized by glioblastoma mutations 1.00
1 0.40
A coordinated kinase and phosphatase network regulates Stu2 recruitment to yeast kinetochores 0.40
1 0.30
Utility of genomic sequencing classifier in managing cytologically indeterminate oncocytic thyroid nodules 0.30
17 5.32
Inhibition of ceramide synthesis ameliorates body wasting in a cancer cachexia model 0.02
Genome-wide CRISPR screen identifies a cytokine–enhancer circuit driving HIF-2α activation in renal cancer 0.06
Targeting Wnt/β-Catenin and circadian regulator restores PRC2/EZH2 controlled chromatin bivalency and suppresses cell state diversity 0.11
Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma 0.89
Rho/ROCK signaling and α-Catenin mediate β-Catenin-driven hyperplasia in the adrenal cortex via adherens junctions 0.67
ATR Safeguards Epithelial-to-Mesenchymal Transition by Countering R-loops and Enabling Transcription Reprogramming 0.94
Allosteric modulation of the solute carrier transporter SLC39A8 potentiates manganese and cadmium uptake 0.11
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion 0.76
Acetyl-CoA carboxylase-1 inhibition increases regulatory T-Cell metabolism and graft-vs-host disease treatment efficacy via mitochondrial fusion 0.13
USP10/GSK3B-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer 0.03
Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease models 0.02
A smooth muscle cell lncRNA controls angiogenesis in chronic limb-threatening ischemia through miR-143-3p/HHIP signaling 0.81
Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer 0.08
SEC61B regulates calcium flux and platelet hyperreactivity in diabetes 0.03
Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma 0.04
Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma 0.50
Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer 0.11
32 4.06
Concurrent versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of “High Risk” Early Breast Cancer: NRG/RTOG 1005 Phase III Trial 0.04
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial. 0.07
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE). 0.23
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer. 0.10
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial. 0.06
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study. 0.01
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease. 0.02
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer. 0.04
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2. 0.04
Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm. 0.08
Integrating Electronic Patient-Reported Outcomes and Palliative Care in Pediatric Advanced Cancer: The PediQUEST Response Multisite Randomized Controlled Trial. 0.31
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2. 0.33
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study. 0.24
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005. 0.04
Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma. 0.79
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer. 0.02
Gemcitabine intravesical system plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with MIBC: primary analysis and biomarker results of SunRISe-4. 0.05
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma. 0.10
Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533. 0.06
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma. 0.03
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results. 0.05
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. 0.03
PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. 0.11
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). 0.02
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. 0.10
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. 0.06
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. 0.05
Multisite Randomized Trial of Inpatient Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation. 0.74
Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. 0.03
Mindfulness and Tai Chi for Cancer Health (MATCH) Study: Primary Outcomes of a Preference-Based Multisite Randomized Comparative Effectiveness Trial. 0.13
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab. 0.04
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. 0.05
2 0.92
PD-1 regulates tumor-infiltrating CD8+ T cells in both a cell-intrinsic and a cell-extrinsic fashion 0.92
Tumor cell heterogeneity drives spatial organization of the intratumoral immune response 0.00
2 0.27
HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort 0.21
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma 0.06
3 1.90
Extent of resection for spread-through air spaces−positive stage IA1-2 non−small cell lung cancer 1.00
Association of chemoradiation, trimodality therapy, or salvage resection with survival in stage II-III esophageal squamous cell carcinoma 0.07
Incidental use of angiotensin system inhibitors during neoadjuvant therapy for esophageal adenocarcinoma: An analysis of survival 0.83
5 2.05
Sprayable Lactococcus lactis-Nanocatalyst Gel for Postsurgical Immunomodulation in Preclinical Oral Squamous Cell Carcinoma 0.83
Rewiring the Fusion Oncoprotein EWSR1::FLI1 in Ewing Sarcoma with Bivalent Small Molecules 0.40
The Allosteric Regulator Inositol Phosphate Dramatically Affects the Efficacy and Selectivity of Inhibitors for Different HDAC Complexes 0.17
Deubiquitinase-Targeting Chimeras Mediated Stabilization of Tumor Suppressive E3 Ligase Proteins as a Strategy for Cancer Therapy 0.58
Engineering of Sono-Activatable Immunogels for Immunometabolism Disorder Normalization Therapy of Breast Cancer 0.07
1 0.14
Few Older Women Are Aware of Guidelines on When to Stop Breast Cancer Screening 0.14
21 5.00
Postpartum breast cancer: evidence for a distinct phenotype 0.26
Sex steroid hormones, gonadotropins, and risk of testicular germ cell tumors: results from the STEED study 0.13
Addressing algorithmic bias in lung cancer screening eligibility 0.25
Impact of age and frailty on acute care use during immune checkpoint inhibitor treatment 0.08
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer 0.50
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials 0.02
Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis 0.08
Frequency and clinical features of germline pathogenic variants in sarcoma: a case-control study 0.77
Prognostic value of visually and computationally-assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030) 0.38
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.01
Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (alliance) 0.18
Treatment exposure-based risk-stratification for care of survivors of childhood cancer: a report from the childhood cancer survivor study 0.09
Gaps in care across the cancer screening continuum for cervical, colorectal, and lung cancers 0.07
Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort 0.03
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer 0.45
Active surveillance for low-risk prostate cancer: long-term utilization and outcomes among Black men 0.82
Survival deficits in young women with breast cancer in sub-Saharan Africa: the African Breast Cancer–Disparities in Outcomes cohort 0.08
Assessing Outcomes Emerging After Conversion to Regular Approval for Cancer Drug Indications Granted Accelerated Approval, 1992-2021 0.67
Breastfeeding after breast cancer in young iBRCA/i carriers 0.02
Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adults 0.10
Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma 0.01
2 0.76
MRE11 proximal polyadenylation site-mediated looping impacts transcription and genomic stability 0.69
Accumulation of succinate suppresses de novo purine synthesis through succinylation-mediated control of the mitochondrial folate cycle 0.07
22 7.04
Evolutionary characterization of lung cancer metastasis 0.00
A pro-carcinogenic bacterial toxin binds claudin-4 to cleave E-cadherin 0.43
Dominant clones leverage developmental epigenomic states to drive ependymoma 0.02
Epigenetic memory of colitis promotes tumour growth 0.83
Androgen activity in the male embryonic hindbrain drives lethal PFA ependymoma 0.01
Catabolism of extracellular glutathione supplies cysteine to support tumours 0.03
Thymic health and immunotherapy outcomes in patients with cancer 0.52
Multidimensional profiling of heterogeneity in supratentorial ependymomas 0.47
A glucocorticoid–FAS axis controls immune evasion during metastatic seeding 0.91
The ubiquitin ligase KLHL6 drives resistance to CD8 T cell dysfunction 0.01
Bidirectional CRISPR screens decode a GLIS3-dependent fibrotic cell circuit 0.70
Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma 0.04
NSD2 targeting reverses plasticity and drug resistance in prostate cancer 0.03
Lymph node environment drives FSP1 targetability in metastasizing melanoma 0.47
In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma 0.79
Neuronal activity-dependent mechanisms of small cell lung cancer pathogenesis 0.41
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy 0.02
Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors 0.26
Structural basis for the dynamic regulation of mTORC1 by amino acids 0.18
Respiratory viral infections awaken metastatic breast cancer cells in lungs 0.01
The mutagenic forces shaping the genomes of lung cancer in never smokers 0.04
Barcoded viral tracing identifies immunosuppressive astrocyte–glioma interactions 0.86
2 0.34
Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models 0.33
Antibody–bottlebrush prodrug conjugates for targeted cancer therapy 0.01
2 0.71
Cancer-associated fibroblasts regulate DNA repair in pancreatic cancer through NDRG1-mediated R-loop processing 0.62
Aberrant amino acid-sensing promotes immunotherapy resistance via the inflammatory cytokine–ZBTB5–mTORC1 axis 0.10
3 1.52
Mutant p53 protein accumulation is selectively targetable by proximity-inducing drugs 0.81
Highly specific intracellular ubiquitination of a small molecule 0.65
ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDAC 0.06
69 27.49
Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial 0.71
Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy 0.00
Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial 1.00
Correction of the molecular phenotype of X-linked Dystonia-Parkinsonism reveals a non-canonical function of BRD4 0.20
Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer 0.99
Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs  0.09
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study 0.81
SMARCB1 missense mutants disrupt SWI/SNF complex stability and remodeling activity 0.26
In vivo CAR T cell generation using retargeted and functionalized lentiviral vectors with reduced immunogenicity 0.76
Single-cell transcriptomics reveals FXR1 as an actionable target for siRNA therapy in ovarian cancer 0.11
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial 0.90
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study 0.10
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in G12C-mutant advanced solid tumors: a first-in-human study 0.04
A large-scale genome-wide association meta-analysis for nevus count provides direct insights into the genetics of melanoma 0.03
Tumor-induced orexigenic imbalance lowers protein appetite and drives early organ wasting symptoms 0.92
Rank signaling drives basal cell-lineage infidelity leading to mammary tumorigenesis 0.05
Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial 0.05
Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer 0.18
FOXJ1 mediates taxane resistance through regulation of microtubule dynamics 0.80
NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss 0.67
Early diagnosis of pancreatic ductal adenocarcinoma by signal-enhanced lateral flow immunoassay: SELFI 0.01
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial 0.03
Modulation of Nudt21 levels reveals dose-dependent roles of alternative polyadenylation in tissue regeneration 0.65
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge 0.06
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis 0.04
Deep Mutational Scanning of FDX1 Identifies Key Structural Determinants of Lipoylation and Cuproptosis 0.47
Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors 0.65
Early genetic evolution of driver mutations in uveal melanoma 0.03
The PIK3CA/AKT pathway drives therapy resistance in rhabdomyosarcoma 0.95
Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinoma 0.93
Therapeutic 6-thio-deoxyguanosine inhibits telomere elongation in cancer cells by inducing a non-productive stalled telomerase complex 0.25
EP300 deficiency leads to chronic replication stress mediated by defective replication fork protection 0.05
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial 0.91
The CTLH ubiquitin ligase substrates ZMYND19 and MKLN1 negatively regulate mTORC1 at the lysosomal membrane 0.58
Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer 0.97
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial 0.86
Bioorthogonal optimized virus immuno-nanomedicine (BOVIN) 0.03
Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia 0.61
Multimodal AI and tumour microenvironment integration predicts metastasis in cutaneous melanoma 0.08
The /EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs 0.30
A non-canonical lymphoblast in refractory childhood T-cell leukaemia 0.02
Pathogenic variants in cause an X-linked neurodevelopmental disorder modulated by NURF complex composition 0.02
On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical models 0.92
Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapies 0.58
BRCA2 deficiency and replication stress drive APOBEC3-Mediated genomic instability 0.06
Genome-wide association study of childhood B-cell acute lymphoblastic leukemia reveals novel African ancestry-specific susceptibility loci 0.00
Leveraging platinum-protein interactions to overcome chemoresistance 0.08
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer 0.03
Dual membrane receptor degradation via folate receptor targeting chimera 0.86
In vivo CRISPR screening in head and neck cancer reveals as an immunotherapy target 0.56
Structural insights into chemoresistance mutants of BCL-2 and their targeting by stapled BAD BH3 helices 0.90
Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial 0.20
Cryo-EM structures of CRAF/MEK1/14-3-3 complexes in autoinhibited and open-monomer states reveal features of RAF regulation 1.00
Tumor cell-adipocyte gap junctions activate lipolysis and contribute to breast tumorigenesis 0.04
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma 0.06
A clonally expanded nodal T-cell population diagnosed as T-cell lymphoma after CAR-T therapy 0.78
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas 0.55
De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer 0.84
Specific oncogene activation of the cell of origin in mucosal melanoma 0.87
The invasion phenotypes of glioblastoma depend on plastic and reprogrammable cell states 0.03
Marked heterogeneity in malaria infection rate in a Malian longitudinal cohort 0.53
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B 0.06
Synthetic carbon-based lanthanide upconversion nanoparticles for enhanced photothermal therapy 0.17
JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms 0.10
Deficits in mitochondrial dynamics and iron balance result in templated insertions 0.32
Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny 0.00
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer 0.61
Molecular patterns and mechanisms of tumorigenesis in HPV-associated and HPV-independent sinonasal squamous cell carcinoma 0.10
A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence 0.06
16 3.94
Age distinguishes selection from causation in cancer genomes 0.80
High-resolution single-cell mapping of clonal hematopoiesis and structural variation in aplastic anemia 0.05
Biallelic variants in the noncoding RNA gene RNU4-2 cause a recessive neurodevelopmental syndrome with distinct white matter changes 0.03
Systematic analysis of snRNA genes reveals frequent variants in dominant and recessive developmental and epileptic encephalopathies 0.03
A repeat expansion in is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions 0.01
CDK4/6 inhibition mitigates chemotherapy-induced expansion of -mutant clonal hematopoiesis 0.03
Global multi-ancestry genome-wide analyses identify genes and biological pathways associated with thyroid cancer and benign thyroid diseases 0.06
Genomic evolution of pancreatic cancer at single-cell resolution 0.05
De novo and inherited dominant variants in U4 and U6 snRNA genes cause retinitis pigmentosa 0.02
A breakage–replication/fusion process explains complex rearrangements and segmental DNA amplification 0.83
Patterns of hypermutation shape tumorigenesis and immunotherapy response in mismatch-repair-deficient glioma 0.04
Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in dedifferentiated endometrial carcinomas 0.69
Rapid epigenomic classification of acute leukemia 0.78
Tamoxifen induces PI3K activation in uterine cancer 0.49
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation 0.02
Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A 0.01
1 0.89
Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer 0.89
1 0.02
IL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer 0.02
18 3.46
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial 0.38
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial 0.79
Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial 0.11
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial 0.01
Enhanced dynamic risk stratification of smoldering multiple myeloma 0.37
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial 0.05
A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial 0.13
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial 0.04
Abemaciclib in meningiomas with somatic or CDK pathway alterations: the phase 2 Alliance A071401 trial 0.28
CD4 T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy 0.00
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma 0.27
Targeting of HIF2-driven cachexia in kidney cancer 0.53
Microbial signals in primary and metastatic brain tumors 0.03
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial 0.11
Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results 0.10
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results 0.07
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial 0.05
Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer 0.16
1 0.90
Systemic reprogramming of tumour immunity via IL-10-mRNA nanoparticles 0.90
1 0.07
TDP-43 loss induces cryptic polyadenylation in ALS/FTD 0.07
1 0.06
C9orf72 hexanucleotide repeat RNA drives transcriptional dysregulation through genome-wide DNA:RNA hybrid G-quadruplexes 0.06
1 0.20
Protein-interaction network analysis reveals the role of Prp19 splicing factor in transcription of both intron-containing and intron-lacking genes 0.20
14 7.39
Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade 0.00
HPV16 E6 oncoprotein promotes microhomology-mediated viral integration by increasing PolΘ protein expression 0.75
Evaluation of targeted and immune combination therapies in a rat model of hormone receptor–positive breast cancer 1.00
Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination–proficient prostate cancer 0.88
Dual-targeted ping-pong CAR T cells: Leveraging peripheral expansion to improve solid tumor immunotherapy 0.04
Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer 0.09
Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell–engineered mesothelin-redirected CAR-NKT cells 0.00
Physiologically based pharmacokinetic model for CAR-T cell delivery and efficacy in solid tumors 0.50
Small-molecule allosteric activator of ubiquitin-specific protease 7 (USP7) 0.79
Functional spectrum of USP7 pathogenic variants in Hao–Fountain syndrome: Insights into the enzyme’s activity, stability, and allosteric modulation 0.36
The E3 ligase HECTD4 regulates COX-2-dependent tumor progression and metastasis 0.97
CDKN1B (p27/kip1) enhances drug-tolerant persister CTCs by restricting polyploidy following mitotic inhibitors 1.00
A degradable form of polyoma small T antigen reveals the high specificity of TAZ in regulating gene expression 0.80
CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor–driven proteome through PARP7 activity 0.21
3 1.79
Prediction of Lobar Emphysema Progression with a CT-Based Foundational Model 0.67
External Testing of a Deep Learning Model for Lung Cancer Risk from Low-Dose Chest CT. 0.13
AI to Reduce the Interval Cancer Rate of Screening Digital Breast Tomosynthesis. 1.00
10 2.15
Lymphoid tissue chemokines limit priming duration to preserve CD8+ T cell functionality 0.03
Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics 0.14
Mechanisms linking cytoplasmic decay of translation-defective mRNA to transcriptional adaptation 0.21
Structural basis for the recruitment and selective phosphorylation of Akt by mTORC2 0.32
A hypoxia-responsive tRNA-derived small RNA confers renal protection through RNA autophagy 0.47
Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNA 0.01
A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors 0.26
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction 0.10
Macrophage-derived oncostatin M repairs the lung epithelial barrier during inflammatory damage 0.62
In vivo CAR T cell generation to treat cancer and autoimmune disease 0.00
11 3.84
Single-nucleotide variant profiling in liquid biopsy with RECO-Cas 0.06
<atl>Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and iBAP1/i loss</atl> 0.73
Accessory microRNA byproducts expand RNA interference via microprocessor-mediated cleavage activation 0.76
Autocrine TGFβ2 enforces a transcriptionally hybrid cell state in Ewing sarcoma 0.08
Phenotypic discovery and therapeutic evaluation of an ITGA3B1-targeting antibody-drug conjugate for bladder cancer 0.00
Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma 0.75
Targeting cancer-associated fibroblasts for real-time intraoperative tumor identification with a spray-on fluorescent probe 0.67
Peptide-MHC–targeted retroviruses enable in vivo expansion and gene delivery to tumor-specific T cells 0.46
Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer 0.29
Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma–GATA3 molecular subgroup 0.03
Combination LIGHT overexpression and checkpoint blockade disrupts the tumor immune environment impacting colorectal liver metastases 0.00
9 1.52
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma 0.38
Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors 0.00
Kras G12C– and G12D–driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models 0.36
A first-in-class small-molecule inhibitor targeting AVIL exhibits safety and antitumor efficacy in preclinical models of glioblastoma 0.08
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses 0.46
Spatial profiling of human pancreatic ductal adenocarcinoma reveals molecular alterations associated with venous invasion 0.01
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer 0.04
Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models 0.05
Podocyte YAP and TAZ hyperactivation drives glomerular epithelial proliferative diseases in mice and humans 0.14
1 0.08
Cancer outcomes in women without upfront surgery for ductal carcinoma in situ: observational cohort study 0.08
2 0.36
Autophagosomes anchor an AKAP11-dependent regulatory checkpoint that shapes neuronal PKA signaling 0.33
Annexin A5 controls VDAC1-dependent mitochondrial Ca2+ homeostasis and determines cellular susceptibility to apoptosis 0.03
4 0.23
Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial 0.09
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis 0.06
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study 0.03
Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial 0.04
16 1.42
Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study 0.17
Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial 0.08
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial 0.06
Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study 0.05
Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study 0.02
A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group 0.11
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials 0.02
Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study 0.04
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial 0.03
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial 0.08
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF V600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study 0.18
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis 0.17
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis 0.13
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial 0.05
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis 0.19
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial 0.05
17 0.85
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer 0.05
Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease 0.04
A Phase 3 Trial of Brepocitinib in Dermatomyositis 0.02
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer 0.03
Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer 0.04
Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors 0.12
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer 0.08
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer 0.05
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer 0.05
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer 0.03
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer 0.06
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC 0.05
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.03
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer 0.06
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer 0.04
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer 0.04
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer 0.07

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.